Last reviewed · How we verify
NCT07139509: UCAR-T_MM-XA
Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma
Phase 1 trial testing allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells in Relapsed/Refractory Multiple Myeloma(MM) in 18 participants. Currently enrolling.
30 July 2028
Quick facts
| Lead sponsor | Xi'an No.3 Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 3 October 2024 |
| Primary completion | 30 July 2028 |
| Estimated completion | 30 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells — full drug profile →
Conditions studied
- Relapsed/Refractory Multiple Myeloma(MM) — all drugs for Relapsed/Refractory Multiple Myeloma(MM) →
Sponsor
Xi'an No.3 Hospital
Who can join
Adults 18 to 75, any sex, with Relapsed/Refractory Multiple Myeloma(MM). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical trial is to learn if allogeneic cord blood-derived CAR-T cell drug works to treat Multiple Myeloma (MM) including Bone-related extramedullary (EMB) disease and extramedullary extraosseous disease(EME) in adults. It will also learn about the safety of the allogeneic cord blood-derived CAR-T cell drug. The main questions it aims to answer are: 1. What adverse events occur and the incidence rate of DLTs within 28 days and UCAR-T-related AEs within 28 days after the allogeneic cord blood-derived CAR-T cell injection for multiple myeloma (MM)? 2. Which dose level is the optimal biological dose (OBD)? 3. What is the overall responserate (ORR), including stringent complete response (sCR), completeresponse (CR),very good partial response (VGPR), partial response (PR), minimal Response (MR) and DOR, PFS, RFS, OS? Participants will: 1. be pretreated with FC regimen, fludarabine (30mg/m²/d, days -5, -4, and -3) and cyclophosphamide (300\~500 mg/m²/d, day -5,-4, and -3). 2. rest for 2 days on Day-2 and Day-1. Tumor burden should be re-evaluated and chemotherapy side effects assessment. 3. receive allogeneic cord blood-derived CAR-T cells infusion 4. Visit the clinic at D28, 1 month, 2 months, 3 months, 4 months, 6 months, 9 months and 1 year after CAR-T cells infusion.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07139509
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Relapsed/Refractory Multiple Myeloma(MM)
Currently open trials in the same condition.
- NCT07100067 — LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma · NA · recruiting
Other Xi'an No.3 Hospital trials
Trials by the same sponsor.
- NCT06390761 — Efficacy of Acupuncture for the Treatment of Parkinson's Disease Related Constipation · NA · recruiting
- NCT06001047 — Head Acupuncture Treat Residual Symptoms After Canalith Repositioning Procedure for BPPV · NA · recruiting
- NCT05561088 — Efficacy and Safety of Head Acupuncture After Mechanical Thrombectomy for Acute Ischemic Stroke · NA · recruiting
- NCT05424978 — Application of Standardized Green Channel Treatment System for Ischemic Stroke in Xi 'an · recruiting
- NCT03607565 — A New Parameter Derived From DSA to Evaluate Cerebral Perfusion · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07139509 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xi'an No.3 Hospital
- Last refreshed: 25 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07139509.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing